Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients

Autor: Emm Strijbis, Frederik Barkhof, Joep Killestein, Eme Coerver, N. F. Kalkers, Zle van Kempen, Zygj van Lierop, B Moraal, AA Toorop, Charlotte E. Teunissen, Eaj Willemse

Publikováno v: Multiple sclerosis journal-experimental, translational and clinical, 7(2). SAGE Publications Inc.
Multiple Sclerosis Journal-Experimental, Translational and Clinical
van Lierop, Z Y G J, Toorop, A A, Coerver, E M E, Willemse, E A J, Strijbis, E M M, Kalkers, N F, Moraal, B, Barkhof, F, Teunissen, C E, Killestein, J & van Kempen, Z L E 2021, ' Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients ', Multiple sclerosis journal-experimental, translational and clinical, vol. 7, no. 2 . https://doi.org/10.1177/20552173211013831

Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either direc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ba49e913fd3b71068caa0700ff5d51f
https://doi.org/10.1177/20552173211013831

Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.

Autor: Gelissen LMY; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Neurology Outpatient Clinic, De Boelelaan 1118, Amsterdam 1081 HV, the Netherlands. Electronic address: l.m.y.gelissen@amsterdamumc.nl., Loveless S; Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, UK., Toorop AA; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Neurology Outpatient Clinic, De Boelelaan 1118, Amsterdam 1081 HV, the Netherlands., Howlett J; Department of Neurology, University Hospital of Wales, Cardiff, UK., Loeff FC; Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands., Rispens T; Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands; Department of Immunopathology, Sanquin Research & Landsteiner Laboratory Academic Medical Centre, Amsterdam, Netherlands., Killestein J; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Neurology Outpatient Clinic, De Boelelaan 1118, Amsterdam 1081 HV, the Netherlands., Tallantyre EC; Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, UK; Department of Neurology, University Hospital of Wales, Cardiff, UK., van Kempen ZLE; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Neurology Outpatient Clinic, De Boelelaan 1118, Amsterdam 1081 HV, the Netherlands.

Publikováno v: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2024 Oct; Vol. 90, pp. 105796. Date of Electronic Publication: 2024 Jul 30.

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).

Autor: Toorop AA; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands a.toorop@amsterdamumc.nl., van Lierop ZY; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Gelissen LM; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Hoitsma E; Department of Neurology, MS Center, Alrijne Hospital, Leiden, The Netherlands., Zeinstra EM; Department of Neurology, Isala, Meppel, The Netherlands., van Rooij LC; Department of Neurology, Maasstad Hospital, Rotterdam, The Netherlands., van Munster CE; Department of Neurology, Amphia Hospital, Breda, The Netherlands., Vennegoor A; Department of Neurology, Flevoziekenhuis, Almere, The Netherlands., Mostert JP; Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands., Wokke BH; Department of Neurology, ErasMS, Erasmus Medical Center, Rotterdam, The Netherlands., Kalkers NF; Department of Neurology, OLVG Hospital, Amsterdam, The Netherlands., Hoogervorst EL; Department of Neurology, St Antonius Hospital, Utrecht, Netherlands., van Eijk JJ; Department of Neurology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Roosendaal CM; Department of Neurology, Slingeland Hospital, Doetinchem, The Netherlands., Kragt JJ; Department of Neurology, Reinier de Graaf Hospital, Delft, The Netherlands., Eurelings M; Department of Neurology, Spaarne Gasthuis, Haarlem, The Netherlands., van Genugten J; Department of Neurology, Ziekenhuisgroep Twente, Almelo, The Netherlands., Nielsen J; Department of Neurology, Ommelander Hospital Groningen, Scheemda, The Netherlands., Sinnige L; Department of Neurology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Kloosterziel ME; Department of Neurology, Wilhelmina Hospital Assen, Assen, The Netherlands., Arnoldus EP; Department of Neurology, Elisabeth TweeSteden Hospital, Tilburg, The Netherlands., van Dijk GW; Department of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Bouvy WH; Department of Neurology, Diakonessenhuis Hospital, Utrecht, The Netherlands., Wessels MH; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Boonkamp L; Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Strijbis EM; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., van Oosten BW; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., De Jong BA; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Lissenberg-Witte BI; Department of Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Barkhof F; Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.; Queen Square MS Centre, Department of Neuroinflammation, Faculty of Brain Sciences, University College London Hospitals and National Institute for Health Research, London, UK., Moraal B; Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Teunissen CE; Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Rispens T; Diagnostic Services and Immunopathology, Sanquin Research, Amsterdam, The Netherlands.; Department of Immunopathology, Landsteiner Laboratory, University of Amsterdam, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands., Uitdehaag BM; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Killestein J; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., van Kempen ZL; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.

Publikováno v: Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2024 Apr 12; Vol. 95 (5), pp. 392-400. Date of Electronic Publication: 2024 Apr 12.

Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.

Autor: Toorop AA; Department of Neurology, MS Center Amsterdam, Amsterdam UMC Location VUMC, Amsterdam, The Netherlands a.toorop@amsterdamumc.nl., van Kempen ZLE; Department of Neurology, MS Center Amsterdam, Amsterdam UMC Location VUMC, Amsterdam, The Netherlands., Steenhuis M; Biologics Laboratory, Department of Immunopathology, Sanquin Diagnostic Services, Amsterdam, The Netherlands., Nielsen J; Department of Neurology, Ommelander Hospital Groningen, Scheemda, The Netherlands., Sinnige LGF; Department of Neurology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands., van Dijk G; Department of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Roosendaal CM; Department of Neurology, Slingeland Hospital, Doetinchem, The Netherlands., Arnoldus EPJ; Department of Neurology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands., Hoitsma E; Department of Neurology, Alrijne Hospital, Leiden, The Netherlands., Lissenberg-Witte BI; Department of Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., de Jong BA; Department of Neurology, MS Center Amsterdam, Amsterdam UMC Location VUMC, Amsterdam, The Netherlands., Oosten BWV; Department of Neurology, MS Center Amsterdam, Amsterdam UMC Location VUMC, Amsterdam, The Netherlands., Strijbis EMM; Department of Neurology, MS Center Amsterdam, Amsterdam UMC Location VUMC, Amsterdam, The Netherlands., Uitdehaag BMJ; Department of Neurology, MS Center Amsterdam, Amsterdam UMC Location VUMC, Amsterdam, The Netherlands., Rispens T; Biologics Laboratory, Department of Immunopathology, Sanquin Diagnostic Services, Amsterdam, The Netherlands.; Landsteiner Laboratory, Amsterdam UMC Location AMC, Amsterdam, The Netherlands., Killestein J; Department of Neurology, MS Center Amsterdam, Amsterdam UMC Location VUMC, Amsterdam, The Netherlands.

Publikováno v: Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2023 Jun; Vol. 94 (6), pp. 482-486. Date of Electronic Publication: 2023 Jan 13.

Association of volumetric MRI measures and disability in MS patients of the same age: Descriptions from a birth year cohort.

Autor: de Ruiter LRJ; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands; MS Center Amsterdam, Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands., Loonstra FC; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands., Jelgerhuis JR; MS Center Amsterdam, Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands., Coerver EME; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands., Toorop AA; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands., van Leeuwen ICE; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands., Noteboom S; MS Center Amsterdam, Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands., Moraal B; MS Center Amsterdam, Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands., Strijbis EMM; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands., Schoonheim MM; MS Center Amsterdam, Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands., Uitdehaag BMJ; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands. Electronic address: bmj.uitdehaag@amsterdamumc.nl.

Publikováno v: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2023 Mar; Vol. 71, pp. 104568. Date of Electronic Publication: 2023 Feb 12.